SUPPLEMENT

Q3 2021 — Earnings infographic

Q3 2021PDF · 1 pages663 KB
Alex Gorsky
Chairman and
Chief Executive Officer
Johnson & Johnson
“Our third-quarter results demonstrate solid performance
across Johnson & Johnson, driven by robust above-market
results in Pharmaceuticals, ongoing recovery in Medical
Devices, and strong growth in Consumer Health. In the face
of evolving marketplace dynamics resulting from the effects
of COVID-19 and other global trends, we have continued
to demonstrate the responsiveness and agility required to
meet the needs of our stakeholders, while also successfully
investing in a pipeline of innovation and key commercial
platforms to drive our future growth. I am incredibly proud
of our Company’s transformative growth over the last decade.
As I prepare to transition the role of CEO to Joaquin Duato
in January, I want to extend my deepest gratitude to our
colleagues around the globe who work tirelessly to deliver
solutions to address the world’s most urgent and unmet
healthcare challenges.”
For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson’s earnings release issued on October 19, 2021, available at
http://www.investor.jnj.com/sales-earnings.cfm.
*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
Non-GAAP measure; excludes the impact of translational currency.
Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation
Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are
based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially
from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-
Looking Statements” included in the Johnson & Johnson earnings release issued on October 19, 2021, as well as the most recently filed Johnson & Johnson
Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future
events or developments.
3rd Quarter 2021 Results
3rd Quarter 2021 Sales
Adjusted Diluted Earnings Per Share*
$2.60 	18.2%
Increased 
Diluted Earnings Per Share
$1.37 	3.0%
Increased 
Worldwide
Increased 
$23.3B 	10.6%*
10.7%
Worldwide
Increased  	Excluding acquisitions/
divestitures on an
operational basis
Note: values may have been rounded
$6.6Medical Devices worldwide reported sales increased 8.0%
or 7.0% operationally1
. Primary operational drivers:
 
Worldwide Medical Devices Sales
Billion
Endocutters	Energy 	Biosurgery
Surgical Vision	Wound Closure	Electrophysiology 	Contact Lens
Billion
$13.0 Worldwide Pharmaceutical SalesPharmaceutical worldwide reported sales increased 13.8%
or 13.2% operationally1
. Primary operational drivers:
Consumer Health worldwide reported sales increased 5.3%
or 4.1% operationally1
. Primary operational drivers:
$3.7 	Worldwide Consumer Health Sales
Billion

-- 1 of 1 --